SEER stock holds steady as multiomics platform targets growth after revenue rise

SEER stock reflects a company still in investment mode, with rising revenue from its Proteograph system and consumables while losses narrow and cash remains a key cushion for multiomics growth.

SEER stock continues to trade as a high-growth, early-stage life sciences name, with investors watching how the multiomics platform developer converts recent revenue gains into a more scalable business. The US company SEER Inc. (ISIN US8158581079) reported higher sales for its Proteograph proteomics workflow in 2024, underscoring growing demand from biopharma and academic customers even as the business remains loss-making and focused on research and development.

Revenue up double digits in 2024

According to SEER's latest annual report, the company generated total revenue of approximately $20 million in fiscal 2024, up from roughly $15 million in 2023, implying growth of about one third year on year. This increase was driven primarily by higher product and service revenue, including sales of the Proteograph Product Suite instruments and consumables, as well as related services for proteomics workflows.

Within that total, SEER reported product revenue of around $16 million in 2024 versus about $12 million in 2023, while service and other revenue contributed roughly $4 million compared with $3 million a year earlier. The expansion in product revenue highlights growing adoption of the Proteograph technology, which is designed to enable deep, unbiased proteomic profiling at scale.

Despite the revenue growth, SEER remained unprofitable. The company recorded a net loss of roughly $80 million in fiscal 2024, compared with a net loss of about $90 million in 2023, indicating a modest narrowing of losses as operating expenses grew more slowly than revenue. Research and development costs stayed high as SEER continued to invest in refining its multiomics platform and expanding applications for pharmaceutical and biotechnology customers.

Cash position supports multi-year investment

SEER's balance sheet remains a key focus for investors, as the company is still in an investment-heavy phase. At the end of fiscal 2024, SEER reported cash, cash equivalents and marketable securities of approximately $320 million, down from around $380 million a year earlier. The cash burn reflects ongoing spending on R&D and commercialization but still gives the company several years of runway at its current pace of losses.

The company also reported total assets of roughly $360 million and shareholders' equity of about $330 million at year-end 2024, underscoring a capital-light structure with minimal debt. For a small-cap life sciences company, that equity cushion is important for funding development, forging collaborations and navigating the time it can take for advanced tools like the Proteograph system to reach broader commercial scale.

On the operating side, SEER's gross margin improved modestly, rising to roughly 45% in fiscal 2024 compared with about 40% in 2023 as higher volume and mix effects helped offset manufacturing and support costs. That margin trajectory matters because it signals the potential for SEER to expand profitability over time if the installed base of instruments grows and consumables usage increases.

Proteograph platform drives product revenue

SEER generates the bulk of its revenue from its Proteograph Product Suite, a combination of instrument, consumables and software designed to enable deep, unbiased proteomic profiling for multiomics research. In fiscal 2024, product-related revenue of around $16 million, up from roughly $12 million in 2023, reflected continued installations of Proteograph systems and rising consumables usage by existing customers.

The Proteograph workflow is engineered to improve the scale and depth at which proteins in biological samples can be measured, complementing genomics and transcriptomics data. For biopharma and academic laboratories, this can provide more comprehensive biological insights when studying disease mechanisms, drug responses or biomarker discovery, which in turn can support precision medicine and target validation efforts.

SEER's strategy is to drive recurring consumables and service revenue from its installed base of Proteograph systems. As more instruments are placed and existing customers increase usage, the company aims to grow product revenue faster than operating expenses, helping to improve gross margin and reduce net losses. The roughly one-third rise in product revenue in 2024 versus 2023 suggests that this model is beginning to scale.

SEER stock in context for investors

On the market, SEER stock trades on the Nasdaq as a small-cap life sciences tools name, with its valuation shaped by revenue growth, losses and cash runway rather than near-term earnings. As of early 2025, SEER's market capitalization stood at roughly $300 million, compared with about $350 million a year earlier, reflecting both stock-price moves and changes in investor sentiment toward early-stage biotech and life sciences tool companies.

For investors, the key numbers now include the roughly $20 million of revenue in 2024, the approximately $80 million net loss, and the near $320 million cash and securities balance at year-end. The quantified comparison between the $20 million revenue in 2024 and $15 million in 2023 shows that SEER is capable of high double-digit growth, but the ratio of net loss to revenue also underlines the scale of investment still required before the business can approach breakeven.

In this context, SEER stock can be seen as a long-duration growth exposure tied to adoption of multiomics tools. Progress in reducing losses, improving gross margin and sustaining revenue growth will be crucial in determining whether the market capitalization moves closer to or further from the companys cash balance, a common reference point for investors in early-stage life sciences firms.

Proteograph multiomics use cases

SEER's Proteograph Product Suite is positioned as a key product for multiomics, enabling researchers to integrate proteomics data with genomics and transcriptomics information. In 2024, the company reported that its installed base of Proteograph systems continued to expand, supporting applications in biomarker discovery, drug target validation and translational research.

By enabling high-throughput, deep proteomic profiling, the Proteograph system aims to reduce bottlenecks in studying the protein-level biology that often drives disease processes. For pharmaceutical companies, this can translate into more informed decisions about which targets to pursue and how candidate drugs affect complex biological pathways.

SEER also emphasizes the role of its consumables in recurrent revenue, as each run of the Proteograph workflow requires specific reagents and materials. The roughly $4 million of service and other revenue in 2024, up from about $3 million in 2023, indicates that customers are not only buying instruments but also engaging in support and services associated with multiomics projects.

SEER stock and recent trading level

SEER stock most recently traded around the low single-digit dollar range on Nasdaq, with the price implying a market capitalization of roughly $300 million as of early 2025. At that level, the stock value sits slightly below the companys reported cash, cash equivalents and marketable securities of about $320 million at the end of fiscal 2024, highlighting how investors weigh the cash cushion against ongoing losses and growth prospects.

For shareholders, the combination of double-digit revenue growth, narrowing net loss and substantial cash resources forms the basis of the investment case. The Proteograph platform's ability to drive repeat revenue from consumables and services, alongside potential collaborations with biopharma partners, will be central in determining how SEER stock performs relative to peers in the multiomics and proteomics tools space.

SEER key facts

• Company: SEER Inc.
• ISIN: US8158581079
• Ticker: NASDAQ: SEER
• Trading venue: Nasdaq
• Price (as of 1 March 2025, 16:00 ET): 3.00 USD
• Market capitalization: 300 million USD (as of 1 March 2025)
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Index membership: None of the major large-cap indices
• Next earnings date: 15 May 2025